Europe Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2027

Europe syndromic multiplex diagnostic market is projected to register a CAGR of 7.0% in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Syndromic multiplex diagnostic is a type of advanced diagnostic test which is utilized for the detection of various types of infection diseases such as infective gastroenteritis, respiratory infection, childhood infections, meningitis, sexually transmitted infections, immunosuppression, hepatitis, eye infections and tropical fever, among other types of infectious diseases. Syndromic multiplex diagnostic test also helps clinicians, healthcare and hospitals for detection of the symptoms and signs of the various types of infectious diseases. In the syndromic multiplex diagnostic, various types of reagents and consumables and instruments and accessories are used which helps in maintaining the accuracy and provide fast diagnosis results. The syndromic multiplex diagnostic testing is used to diagnose of 22 respiratory pathogens simultaneously.

Some of the major factors contributing to the growth of the Europe syndromic multiplex diagnostic market are:

growing adoption of molecular diagnostics growing adoption of molecular diagnostics

Growing prevalence of infection diseases

Market Players:

The key market players for Europe syndromic multiplex diagnostic market are listed below:

GenMark Diagnostics, Inc.

QuantuMDx Group Ltd.

BioFire Diagnostics (a subsidiary of bioMerieux SA)

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific Inc.

Siemens Healthcare GmbH

QIAGEN

Hologic, Inc.

F. Hoffmann-La Roche Ltd

BD

Danaher

Curetis

Abbott

DiaSorin S.p.A.

Bosch Healthcare Solutions GmbH (a subsidiary of Robert Bosch GmbH)

Biocartis

Luminex Corporation

Seegene Inc.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 OBJECTIVES OF THE STUDY
• 1.2 MARKET DEFINITION
• 1.3 OVERVIEW OF EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET
• 1.4 LIMITATIONS
• 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

• 2.1 MARKETS COVERED
• 2.2 GEOGRAPHICAL SCOPE
• 2.3 YEARS CONSIDERED FOR THE STUDY
• 2.4 CURRENCY AND PRICING
• 2.5 DBMR TRIPOD DATA VALIDATION MODEL
• 2.6 MULTIVARIATE MODELLING
• 2.7 PRODUCTS AND SERVICES LIFELINE CURVE
• 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
• 2.9 DBMR MARKET POSITION GRID
• 2.10 VENDOR SHARE ANALYSIS
• 2.11 SECONDARY SOURCES
• 2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

• 5.1 DRIVERS
  • 5.1.1 GROWING PREVALENCE OF INFECTION DISEASES
  • 5.1.2 GROWING ADOPTION OF MOLECULAR DIAGNOSTICS
  • 5.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING
  • 5.1.4 INCREASING DEMAND FOR ACCURATE AND FAST DIAGNOSTIC RESULTS
  • 5.1.5 IMPROVING DIAGNOSIS SEEKING RATE
• 5.2 RESTRAINTS
  • 5.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS
  • 5.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC
• 5.3 OPPORTUNITIES
  • 5.3.1 INCREASING DIAGNOSTIC HEALTHCARE EXPENDITURE
  • 5.3.2 INTRODUCTION OF TECHNOLOGICALLY ADVANCED PRODUCTS
• 5.4 CHALLENGES
  • 5.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF DIAGNOSTIC PRODUCTS
  • 5.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS

6 IMPACT OF COVID-19 ON EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET

• 6.1 IMPACT ANALYSIS ON DEMAND
• 6.2 CONCLUSION

7 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES

• 7.1 OVERVIEW
• 7.2 REAGENTS & CONSUMABLES
• 7.3 INSTRUMENTS & ACCESSORIES
• 7.4 SOFTWARE & SERVICES

8 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE

• 8.1 OVERVIEW
• 8.2 VIRAL
  • 8.2.1 RHINOVIRUS
  • 8.2.2 ROTAVIRUS
  • 8.2.3 ADENOVIRUS
  • 8.2.4 CORONAVIRUS
  • 8.2.5 OTHERS
• 8.3 BACTERIAL
  • 8.3.1 PNEUMONIAE
  • 8.3.2 BORDETELLA PERTUSSIS
  • 8.3.3 STAPHYLOCOCCUS
  • 8.3.4 OF OTHERS
• 8.4 PARASITES
• 8.5 FUNGAL
• 8.6 OTHERS

9 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE

• 9.1 OVERVIEW
• 9.2 RESPIRATORY INFECTIONS
• 9.3 GASTROENTERITIS
• 9.4 SEXUALLY TRANSMITTED INFECTIONS
• 9.5 HEPATITIS
• 9.6 TROPICAL FEVER
• 9.7 MENINGITIS
• 9.8 CHILDHOOD INFECTIONS
• 9.9 IMMUNOSUPPRESSION
• 9.10 EYE INFECTIONS

10 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE

• 10.1 OVERVIEW
• 10.2 RESPIRATORY PANEL
• 10.3 GI-ENTERIC PANEL
• 10.4 SEXUALLY TRANSMITTED DISEASE PANEL
• 10.5 BLOOD-SEPSIS PANEL
• 10.6 MENINGITIS PANEL
• 10.7 OTHERS

11 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER

• 11.1 OVERVIEW
• 11.2 HOSPITALS
• 11.3 CLINICAL LABORATORIES
• 11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
• 11.5 RESEARCH INSTITUTES
• 11.6 PHYSICIAN OFFICE LAB'S
• 11.7 OTHERS

12 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY GEOGRAPHY

• 12.1 EUROPE
  • 12.1.1 GERMANY
  • 12.1.2 U.K.
  • 12.1.3 FRANCE `
  • 12.1.4 ITALY
  • 12.1.5 SPAIN
  • 12.1.6 SWITZERLAND
  • 12.1.7 NETHERLANDS
  • 12.1.8 RUSSIA
  • 12.1.9 BELGIUM
  • 12.1.10 TURKEY
  • 12.1.11 REST OF EUROPE

13 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, COMPANY LANDSCAPE

• 13.1 COMPANY SHARE ANALYSIS: EUROPE

14 SWOT ANALYSIS

15 COMPANY PROFILE

• 15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMERIEUX SA)
  • 15.1.1 COMPANY SNAPSHOT
  • 15.1.2 REVENUE ANALYSIS
  • 15.1.3 COMPANY SHARE ANALYSIS
  • 15.1.4 PRODUCT PORTFOLIO
  • 15.1.5 RECENT DEVELOPMENTS
• 15.2 SIEMENS HEALTHCARE GMBH
  • 15.2.1 COMPANY SNAPSHOT
  • 15.2.2 REVENUE ANALYSIS
  • 15.2.3 COMPANY SHARE ANALYSIS
  • 15.2.4 PRODUCT PORTFOLIO
  • 15.2.5 RECENT DEVELOPMENTS
• 15.3 F. HOFFMANN-LA ROCHE LTD
  • 15.3.1 COMPANY SNAPSHOT
  • 15.3.2 REVENUE ANALYSIS
  • 15.3.3 COMPANY SHARE ANALYSIS
  • 15.3.4 PRODUCT PORTFOLIO
  • 15.3.5 RECENT DEVELOPMENT
• 15.4 THERMO FISHER SCIENTIFIC INC.
  • 15.4.1 COMPANY SNAPSHOT
  • 15.4.2 REVENUE ANALYSIS
  • 15.4.3 COMPANY SHARE ANALYSIS
  • 15.4.4 PRODUCT PORTFOLIO
  • 15.4.5 RECENT DEVELOPMENT
• 15.5 BD
  • 15.5.1 COMPANY SNAPSHOT
  • 15.5.2 REVENUE ANALYSIS
  • 15.5.3 COMPANY SHARE ANALYSIS
  • 15.5.4 PRODUCT PORTFOLIO
  • 15.5.5 RECENT DEVELOPMENTS
• 15.6 SEEGENE INC.
  • 15.6.1 COMPANY SNAPSHOT
  • 15.6.2 REVENUE ANALYSIS
  • 15.6.3 PRODUCT PORTFOLIO
  • 15.6.4 RECENT DEVELOPMENTS
• 15.7 ABBOTT
  • 15.7.1 COMPANY SNAPSHOT
  • 15.7.2 REVENUE ANALYSIS
  • 15.7.3 PRODUCT PORTFOLIO
  • 15.7.4 RECENT DEVELOPMENT
• 15.8 APPLIED BIOCODE, INC.
  • 15.8.1 COMPANY SNAPSHOT
  • 15.8.2 PRODUCT PORTFOLIO
  • 15.8.3 RECENT DEVELOPMENTS
• 15.9 BIOCARTIS
  • 15.9.1 COMPANY SNAPSHOT
  • 15.9.2 REVENUE ANALYSIS
  • 15.9.3 PRODUCT PORTFOLIO
  • 15.9.4 RECENT DEVELOPMENT
• 15.10 BIO-RAD LABORATORIES, INC.
  • 15.10.1 COMPANY SNAPSHOT
  • 15.10.2 REVENUE ANALYSIS
  • 15.10.3 PRODUCT PORTFOLIO
  • 15.10.4 RECENT DEVELOPMENT
• 15.11 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH)
  • 15.11.1 COMPANY SNAPSHOT
  • 15.11.2 REVENUE ANALYSIS
  • 15.11.3 PRODUCT PORTFOLIO
  • 15.11.4 RECENT DEVELOPMENT
• 15.12 CURETIS
  • 15.12.1 COMPANY SNAPSHOT
  • 15.12.2 PRODUCT PORTFOLIO
  • 15.12.3 RECENT DEVELOPMENT
• 15.13 DANAHER
  • 15.13.1 COMPANY SNAPSHOT
  • 15.13.2 REVENUE ANALYSIS
  • 15.13.3 PRODUCT PORTFOLIO
  • 15.13.4 RECENT DEVELOPMENT
• 15.14 DIASORIN S.P.A.
  • 15.14.1 COMPANY SNAPSHOT
  • 15.14.2 REVENUE ANALYSIS
  • 15.14.3 PRODUCT PORTFOLIO
  • 15.14.4 RECENT DEVELOPMENTS
• 15.15 GENMARK DIAGNOSTICS, INC.
  • 15.15.1 COMPANY SNAPSHOT
  • 15.15.2 REVENUE ANALYSIS
  • 15.15.3 PRODUCT PORTFOLIO
  • 15.15.4 RECENT DEVELOPMENTS

• 15.16 HOLOGIC, INC.
  • 15.16.1 COMPANY SNAPSHOT
  • 15.16.2 REVENUE ANALYSIS
  • 15.16.3 PRODUCT PORTFOLIO
  • 15.16.4 RECENT DEVELOPMENTS
• 15.17 LUMINEX CORPORATION
  • 15.17.1 COMPANY SNAPSHOT
  • 15.17.2 REVENUE ANALYSIS
  • 15.17.3 PRODUCT PORTFOLIO
  • 15.17.4 RECENT DEVELOPMENT
• 15.18 NANOMIX, INC.
  • 15.18.1 COMPANY SNAPSHOT
  • 15.18.2 PRODUCT PORTFOLIO
  • 15.18.3 RECENT DEVELOPMENTS
• 15.19 PROMINEX
  • 15.19.1 COMPANY SNAPSHOT
  • 15.19.2 PRODUCT PORTFOLIO
  • 15.19.3 RECENT DEVELOPMENT
• 15.20 QIAGEN
  • 15.20.1 COMPANY SNAPSHOT
  • 15.20.2 REVENUE ANALYSIS
  • 15.20.3 PRODUCT PORTFOLIO
  • 15.20.4 RECENT DEVELOPMENT
• 15.21 QUANTUMDX GROUP LTD.
  • 15.21.1 COMPANY SNAPSHOT
  • 15.21.2 PRODUCT PORTFOLIO
  • 15.21.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

LIST OF TABLES

• TABLE 1 COST OF THE PRODUCT
• TABLE 2 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
• TABLE 3 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
• TABLE 4 EUROPE REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 5 EUROPE INSTRUMENTS & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 6 EUROPE SOFTWARE & SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 7 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 8 EUROPE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 9 EUROPE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 10 EUROPE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 11 EUROPE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 12 EUROPE PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 13 EUROPE FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 14 EUROPE OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 15 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
• TABLE 16 EUROPE RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 17 EUROPE GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 18 EUROPE SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 19 EUROPE HEPATITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 20 EUROPE TROPICAL FEVER IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 21 EUROPE MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 22 EUROPE CHILDHOOD INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 23 EUROPE IMMUNOSUPPRESSION IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 24 EUROPE EYE INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 25 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, LIFELINE CURVE, 2018-2027 (USD MILLION)
• TABLE 26 EUROPE RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 27 EUROPE GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 28 EUROPE SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 29 EUROPE BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 30 EUROPE MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 31 EUROPE OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 32 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
• TABLE 33 EUROPE HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 34 EUROPE CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 35 EUROPE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 36 EUROPE RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 37 EUROPE PHYSICIAN OFFICE LAB'S IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 38 EUROPE OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
• TABLE 39 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
• TABLE 40 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
• TABLE 41 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 42 EUROPE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 43 EUROPE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 44 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
• TABLE 45 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
• TABLE 46 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
• TABLE 47 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
• TABLE 48 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 49 GERMANY VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 50 GERMANY BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 51 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
• TABLE 52 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
• TABLE 53 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
• TABLE 54 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
• TABLE 55 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 56 U.K. VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 57 U.K. BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 58 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
• TABLE 59 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
• TABLE 60 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
• TABLE 61 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
• TABLE 62 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 63 FRANCE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 64 FRANCE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 65 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
• TABLE 66 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
• TABLE 67 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
• TABLE 68 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
• TABLE 69 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 70 ITALY VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 71 ITALY BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 72 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
• TABLE 73 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
• TABLE 74 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
• TABLE 75 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
• TABLE 76 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 77 SPAIN VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 78 SPAIN BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 79 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
• TABLE 80 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
• TABLE 81 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
• TABLE 82 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
• TABLE 83 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 84 SWITZERLAND VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 85 SWITZERLAND BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 86 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
• TABLE 87 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
• TABLE 88 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
• TABLE 89 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
• TABLE 90 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 91 NETHERLANDS VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 92 NETHERLANDS BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 93 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
• TABLE 94 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
• TABLE 95 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
• TABLE 96 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
• TABLE 97 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 98 RUSSIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 99 RUSSIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 100 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
• TABLE 101 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
• TABLE 102 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
• TABLE 103 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
• TABLE 104 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 105 BELGIUM VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 106 BELGIUM BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 107 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
• TABLE 108 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
• TABLE 109 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
• TABLE 110 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
• TABLE 111 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 112 TURKEY VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 113 TURKEY BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
• TABLE 114 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
• TABLE 115 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
• TABLE 116 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
• TABLE 117 REST OF EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)

LIST OF FIGURES

• FIGURE 1 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION
• FIGURE 2 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION
• FIGURE 3 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS
• FIGURE 4 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET : EUROPE VS REGIONAL MARKET ANALYSIS
• FIGURE 5 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET : COMPANY RESEARCH ANALYSIS
• FIGURE 6 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
• FIGURE 7 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
• FIGURE 8 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
• FIGURE 9 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION
• FIGURE 10 GROWING PREVALENCE OF INFECTION DISEASES AND GROWING ADOPTION OF MOLECULAR DIAGNOSTICS ARE EXPECTED TO DRIVE THE EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
• FIGURE 11 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2020 & 2027
• FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET
• FIGURE 13 PREVALENCE OF CHRONIC DISEASES
• FIGURE 14 PERCENTAGE OF DEATHS WORLDWIDE
• FIGURE 15 TOTAL CASES OF CORONAVIRUS IN NORTH AMERICA
• FIGURE 16 TOTAL CASES OF CORONAVIRUS IN EUROPE
• FIGURE 17 TOTAL CASES OF CORONAVIRUS IN ASIA-PACIFIC
• FIGURE 18 TOTAL CASES OF CORONAVIRUS IN SOUTH AMERICA
• FIGURE 19 TOTAL CASES OF CORONAVIRUS IN MIDDLE EAST AND AFRICA
• FIGURE 20 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS
• FIGURE 21 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2019
• FIGURE 22 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2019-2027 (USD MILLION)
• FIGURE 23 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, CAGR (2020-2027)
• FIGURE 24 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, LIFELINE CURVE
• FIGURE 25 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2019
• FIGURE 26 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2019-2027 (USD MILLION)
• FIGURE 27 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2020-2027)
• FIGURE 28 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE
• FIGURE 29 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2019
• FIGURE 30 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2019-2027 (USD MILLION)
• FIGURE 31 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2020-2027)
• FIGURE 32 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE
• FIGURE 33 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2019
• FIGURE 34 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2019-2027 (USD MILLION)
• FIGURE 35 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2020-2027)
• FIGURE 36 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE
• FIGURE 37 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2019
• FIGURE 38 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2019-2027 (USD MILLION)
• FIGURE 39 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2020-2027)
• FIGURE 40 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
• FIGURE 41 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2019)
• FIGURE 42 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2019)
• FIGURE 43 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027)
• FIGURE 44 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027)
• FIGURE 45 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES (2018-2027)
• FIGURE 46 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2019 (%)